This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
A look at Idorsia's phase III trials results for its resistant hypertension drug, Aprocitentan
Ticker(s): IDRSFWho's the expert?
Institution: Self-employed
- Endocrinologist, practising for over a decade in south-eastern United States at a regional Diabetes-Endocrine Center of Excellence, in a solo, office-based, single-specialty, out-patient community setting, with a staff of 10
- treats 500 patients with T2D and NASH
- experience of reviewing & presenting literature at loco-regional conferences as a subject matter Expert & Key Opinion Leader on a large variety of Endocrine disorders & related pharmaco-therapeutic agents.
Interview GoalDiscussing the current treatment landscape for resistant hypertension and PRECISION, the Phase 3 study investigating Aprocitentan, a dual endothelin receptor antagonist.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
